Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

HERizon-Breast: a ctDNA-guided adaptive study of sequential anti-HER2 therapy

Phase 2 ctDNA-guided study in unresectable locally advanced or metastatic HER2-positive breast cancer. The registry primary outcome is the proportion who maintain a complete response and a molecular complete response. ClinicalTrials.gov lists the study as recruiting.

Memorial Sloan Kettering Cancer Center